The NFκB inhibitor, SN50, induces differentiation of glioma stem cells and suppresses their oncogenic phenotype

References

• Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, et al, European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups, National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10:459 - 66; http://dx.doi.org/10.1016/S1470-2045(09)70025-7; PMID: 19269895
   PubMed Web of Science ®Google Scholar
• Lee J, Son MJ, Woolard K, Donin NM, Li A, Cheng CH, Kotliarova S, Kotliarov Y, Walling J, Ahn S, et al. Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells. Cancer Cell 2008; 13:69 - 80; http://dx.doi.org/10.1016/j.ccr.2007.12.005; PMID: 18167341
   PubMed Web of Science ®Google Scholar
• Grossman SA, Ye X, Piantadosi S, Desideri S, Nabors LB, Rosenfeld M, Fisher J, NABTT CNS Consortium. Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin Cancer Res 2010; 16:2443 - 9; http://dx.doi.org/10.1158/1078-0432.CCR-09-3106; PMID: 20371685
   PubMed Web of Science ®Google Scholar
• Visvader JE, Lindeman GJ. Cancer stem cells: current status and evolving complexities. Cell Stem Cell 2012; 10:717 - 28; http://dx.doi.org/10.1016/j.stem.2012.05.007; PMID: 22704512
   PubMed Web of Science ®Google Scholar
• Akhtar K, Bussen W, Scott SP. Cancer stem cells - from initiation to elimination, how far have we reached? (Review). [Review] Int J Oncol 2009; 34:1491 - 503; PMID: 19424566
   PubMed Web of Science ®Google Scholar
• Becker MW, Jordan CT. Leukemia stem cells in 2010: current understanding and future directions. Blood Rev 2011; 25:75 - 81; http://dx.doi.org/10.1016/j.blre.2010.11.001; PMID: 21216511
   PubMed Web of Science ®Google Scholar
• Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006; 444:756 - 60; http://dx.doi.org/10.1038/nature05236; PMID: 17051156
   PubMed Web of Science ®Google Scholar
• Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003; 100:3983 - 8; http://dx.doi.org/10.1073/pnas.0530291100; PMID: 12629218
   PubMed Web of Science ®Google Scholar
• Sanai N, Alvarez-Buylla A, Berger MS. Neural stem cells and the origin of gliomas. N Engl J Med 2005; 353:811 - 22; http://dx.doi.org/10.1056/NEJMra043666; PMID: 16120861
   PubMed Web of Science ®Google Scholar
• Cheng L, Bao S, Rich JN. Potential therapeutic implications of cancer stem cells in glioblastoma. Biochem Pharmacol 2010; 80:654 - 65; http://dx.doi.org/10.1016/j.bcp.2010.04.035; PMID: 20457135
   PubMed Web of Science ®Google Scholar
• Piccirillo SG, Reynolds BA, Zanetti N, Lamorte G, Binda E, Broggi G, Brem H, Olivi A, Dimeco F, Vescovi AL. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 2006; 444:761 - 5; http://dx.doi.org/10.1038/nature05349; PMID: 17151667
   PubMed Web of Science ®Google Scholar
• Chan XH, Nama S, Gopal F, Rizk P, Ramasamy S, Sundaram G, Ow GS, Ivshina AV, Tanavde V, Haybaeck J, et al. Targeting glioma stem cells by functional inhibition of a prosurvival oncomiR-138 in malignant gliomas. Cell Rep 2012; 2:591 - 602; http://dx.doi.org/10.1016/j.celrep.2012.07.012; PMID: 22921398
   PubMed Web of Science ®Google Scholar
• Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De Vitis S, Fiocco R, Foroni C, Dimeco F, Vescovi A. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 2004; 64:7011 - 21; http://dx.doi.org/10.1158/0008-5472.CAN-04-1364; PMID: 15466194
   PubMed Web of Science ®Google Scholar
• McCord AM, Jamal M, Shankavaram UT, Lang FF, Camphausen K, Tofilon PJ. Physiologic oxygen concentration enhances the stem-like properties of CD133+ human glioblastoma cells in vitro. Mol Cancer Res 2009; 7:489 - 97; http://dx.doi.org/10.1158/1541-7786.MCR-08-0360; PMID: 19372578
   PubMed Web of Science ®Google Scholar
• Garner JM, Fan M, Yang CH, Du Z, Sims M, Davidoff AM, Pfeffer LM. Constitutive activation of signal transducer and activator of transcription 3 (STAT3) and nuclear factor κB signaling in glioblastoma cancer stem cells regulates the Notch pathway. J Biol Chem 2013; 288:26167 - 76; http://dx.doi.org/10.1074/jbc.M113.477950; PMID: 23902772
   PubMed Web of Science ®Google Scholar
• Frank NY, Schatton T, Frank MH. The therapeutic promise of the cancer stem cell concept. J Clin Invest 2010; 120:41 - 50; http://dx.doi.org/10.1172/JCI41004; PMID: 20051635
   PubMed Web of Science ®Google Scholar
• Fotovati A, Abu-Ali S, Wang PS, Deleyrolle LP, Lee C, Triscott J, Chen JY, Franciosi S, Nakamura Y, Sugita Y, et al. YB-1 bridges neural stem cells and brain tumor-initiating cells via its roles in differentiation and cell growth. Cancer Res 2011; 71:5569 - 78; http://dx.doi.org/10.1158/0008-5472.CAN-10-2805; PMID: 21730024
   PubMed Web of Science ®Google Scholar
• Zhuang W, Li B, Long L, Chen L, Huang Q, Liang Z. Induction of autophagy promotes differentiation of glioma-initiating cells and their radiosensitivity. Int J Cancer 2011; 129:2720 - 31; http://dx.doi.org/10.1002/ijc.25975; PMID: 21384342
   PubMed Web of Science ®Google Scholar
• Sunayama J, Sato A, Matsuda K, Tachibana K, Suzuki K, Narita Y, Shibui S, Sakurada K, Kayama T, Tomiyama A, et al. Dual blocking of mTor and PI3K elicits a prodifferentiation effect on glioblastoma stem-like cells. Neuro Oncol 2010; 12:1205 - 19; PMID: 20861085
   PubMed Web of Science ®Google Scholar
• Naugler WE, Karin M. NF-kappaB and cancer-identifying targets and mechanisms. Curr Opin Genet Dev 2008; 18:19 - 26; http://dx.doi.org/10.1016/j.gde.2008.01.020; PMID: 18440219
   PubMed Web of Science ®Google Scholar
• Hoesel B, Schmid JA. The complexity of NF-κB signaling in inflammation and cancer. Mol Cancer 2013; 12:86; http://dx.doi.org/10.1186/1476-4598-12-86; PMID: 23915189
   PubMed Web of Science ®Google Scholar
• Nogueira L, Ruiz-Ontañon P, Vazquez-Barquero A, Moris F, Fernandez-Luna JL. The NFκB pathway: a therapeutic target in glioblastoma. Oncotarget 2011; 2:646 - 53; PMID: 21896960
   PubMed Web of Science ®Google Scholar
• Lin YZ, Yao SY, Veach RA, Torgerson TR, Hawiger J. Inhibition of nuclear translocation of transcription factor NF-kappa B by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence. J Biol Chem 1995; 270:14255 - 8; http://dx.doi.org/10.1074/jbc.270.24.14255; PMID: 7782278
   PubMed Web of Science ®Google Scholar
• Abate A, Oberle S, Schröder H. Lipopolysaccharide-induced expression of cyclooxygenase-2 in mouse macrophages is inhibited by chloromethylketones and a direct inhibitor of NF-kappa B translocation. Prostaglandins Other Lipid Mediat 1998; 56:277 - 90; http://dx.doi.org/10.1016/S0090-6980(98)00061-6; PMID: 9990673
   PubMed Web of Science ®Google Scholar